Back to search

Netherlands· NL-8c604a9ab4c0

RIULVY 348 mg maagsapresistente capsules, hard

A tegomil fumarat product containing tegomilfumaraat, registered in Netherlands by Neuraxpharm Pharmaceuticals S.L.. The same ATC class is registered in 7 of our 19 countries.

ATC L04AX10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRIULVY 348 mg maagsapresistente capsu…ATCL04AX10REGISTER NO.NL-8c604a9ab4c0PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Tegomil fumarat is registered in 7 of 19 countries.

Countries holding a registration under ATC L04AX10 (tegomil fumarat), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose

Tegomil fumarat · ATC L04AX10

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TEGOMILFUMARAAT
Manufacturer
Neuraxpharm Pharmaceuticals S.L.
Country
Netherlands (NL)
ATC code
L04AX10
ATC class
Tegomil fumarat
Defined daily dose
0.696 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1947

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tegomil fumarat in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tegomil fumarat products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d66e5873-8504-4e35-a2cf-20bcdb8a429f
GET /v1/drugs/d66e5873-8504-4e35-a2cf-20bcdb8a429f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Maagsapresistente capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/riulvy-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tegomil fumarate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133180",
  "excipients": [
    "BRILJANTBLAUW FCF (E 133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "KALIUMHYDROXIDE (E 525)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)",
    "TRIETHYLCITRAAT (E 1505)",
    "WITTE INKT"
  ],
  "substances": [
    "TEGOMILFUMARAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/07/28",
  "procedure_number": "EMEA/H/C/006427",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1947",
  "additional_monitoring": "N"
}

See everything about tegomil fumarat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.